摘要
目的探讨血清肿瘤标记物在FOLFIRI方案治疗晚期结直肠癌患者疗效评价中的意义。方法对50例确诊的晚期结直肠癌患者,采用FOLFIRI方案治疗,观察治疗前后患者血清肿瘤标记物TPS、CEA、CA199和CA242的动态变化和近期疗效。结果血清肿瘤标记物CEA、CA242和TPS水平RR组(CR+PR)化疗后显著减低(P<0.05),其中TPS降低最早,CEA则在治疗6～8周后才出现变化;4种肿瘤标记物评价与临床疗效评价的总一致性比较差异不显著(P>0.05);临床客观评价病情进展和有效率时(PD+RR)符合率比较有显著性差异(P<0.05)。联合检测TPS、CEA和CA2423个指标,则总符合率为85.9%。结论TPS、CEA和CA242联合检测,对采用FOLFIRI方案治疗晚期结直肠癌患者的疗效评价有重要意义。
Objective To study the significance of serum tumor biomarkers in evaluating the effects of advanced colorectal cancer treated with FOLFIRI.Methods 50 patients with advanced colorectal cancer were treated with FOLFIRI.The CEA,CA242,CA199 and TPS were measured before and after treatment.Results CEA,CA242 and TPS levels were significantly lowered in patients responded（CR＋PR）to treatments（P〈0.05）.TPS was the first biomarker to decrease,whereas CEA declination was occurred 6～8 weeks after treatment initiation.The correlation between the 4 tumor biomarkers evaluation and the clinical effect evaluation showed no statistically significant（P〉0.05）,but their respective coincidences with the clinical objective evaluation of disease progression and the total response rate（RR＋PD）differed significantly（P〈0.05）.When combining the 3 indices of TPS,CEA and CA242,their total coincidence reached 85.9% with the clinical evaluation.Conclusion Monitoring the changes in serum CEA,TPS and CA242 levels may enhance the consistency of laboratory findings with the clinical evaluation of advanced colorectal cancer treated with FOLFIRI.
出处
《实用癌症杂志》
2008年第6期586-589,共4页
The Practical Journal of Cancer
关键词
结直肠癌
肿瘤标记物
Colorectal cancer
Tumor biomarkers
